On July 17, 2022, the zaodx world cancer early screening conference 'healthy China · early screening first' came to an end in Guangzhou. During the meeting, Dr. Zhang Lianglu, chairman and general manager of Wuhan amison life science and Technology Co., Ltd., received a special interview from the Organizing Committee of the early screening conference and shared his unique views on how to promote the development of the early screening industry and how to accelerate the commercialization of early screening products.
01 Early screening of tumor is an urgent and imperative action plan in China.
Early screening: what do you think of early screening for tumors?
Dr. Zhang Lianglu: early screening and diagnosis of tumors is an urgent and imperative action plan in China. At present, the overall incidence rate and mortality rate of cancer in our country are among the highest in the world and showing a continuous rising trend. From the international experience, early screening, early diagnosis and early treatment are the most effective methods for cancer prevention and control, which can effectively reduce the incidence and mortality of cancer. Such effective experience should also be further promoted in China. At present, China's cancer screening action has been gradually promoted, and some places have achieved initial results, but the overall cancer screening penetration rate is still low. According to the outline of the 'healthy China 2030' plan, the overall 5-year survival rate of cancer will be increased by 15% by 2030. Therefore, for more preventable and controllable cancers, China should accelerate the speed of early screening and early diagnosis to achieve a broader population coverage.
02 The development of early screening for cancer needs to be driven by innovative technical products and correct health concepts.
Early screening: combined with your work experience, how do you think to better promote the development of early screening for tumors?
Dr. Zhang Lianglu: at present, the development of early cancer screening needs to be driven by new technologies, new products, new methods and correct health concepts. In order to improve this situation and promote the development of early cancer screening, we need to encourage technological innovation, increase capital investment, and accelerate market access, medical insurance licensing and diversified payment system to support the development of early cancer screening; At the legal level, we should speed up the registration and certification process of early screening and early diagnosis products for cancer, so that truly effective products can enter the clinic more quickly; At the level of improving the people's awareness of screening, we should increase the efforts of science popularization and education, and mobilize the whole social forces to participate in the large-scale action of early screening and early diagnosis of cancer, and make joint efforts to make early screening and early diagnosis of cancer benefit thousands of families.
03 The establishment and improvement of relevant government policies is an important factor for the commercialization of early screening for cancer.
Early screening: what do you think are the main challenges facing the early screening industry?
Dr. Zhang Lianglu: for early screening and diagnosis of cancer, we are faced with at least five major challenges. The first is technological innovation. No matter the market maturity, the selection of platforms, the use of markers or the calculation of results, we need to design and develop in combination with clinical practice; Second, in terms of product design and development, it is necessary to comprehensively consider the actual situation of the country, pay attention to the four basic aspects of 'early, accurate, convenient and inclusive', develop early screening and early diagnosis products for tumors that can be found early, have excellent performance, are easy to operate and are affordable, and enter the medical system to truly benefit the people; The third is the registration and application process. At present, many tumor early screening products are domestic or even international initiatives. In terms of approval, more evidence-based medical evidence, clinical evidence, and even expert consensus guidelines are needed to help these products register and obtain evidence faster; The fourth is the detection link. From the perspective of the detection platform, the realization of large-scale population screening requires a complete laboratory platform system and a sound laboratory operation process; Fifth, in terms of the overall business environment, the establishment and improvement of relevant government policies are important factors for the commercialization of tumors, such as market access and medical insurance payment; In addition, how to grasp the global market opportunities and how to make Chinese innovative products go global are also issues that we Chinese innovative enterprises need to consider and face.
Profile of Dr. Zhang LiangluChairman and general manager of Wuhan amison Life Technology Co., Ltd
Ph.D. in cell biology, Wuhan University, senior engineer, alumni of Harvard Business School HBx and China Europe Business School; Director of Chu Merchants Association; Executive director of Hubei Young Entrepreneurs Association; Director of Hubei Society for clinical evaluation of drugs and medical devices; Member of the Collaborative Group on gastric cancer markers of China anticancer association; Member of the Expert Committee on molecular diagnosis; Vice chairman of science popularization and teaching special committee of Hubei immunology society; Leading talents of the Ministry of industry and information technology, optical valley 3551 entrepreneurial talents, Hubei young talents, Yangtze River students, vice president of Wuhan University Economic Management Branch, vice president of central China branch of shell University, etc.
Focus on the needs of diagnosis and treatment
Take striving innovators as the fundamental